Aurobindo gets FDA OK for generic Firazyr
Icatibant injection is indicated for treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
Aurobindo Pharma’s subsidiary Eugia Pharma Specialities has received the Food and Drug Administration’s blessing for Icatibant injection, 30 mg, which is the generic of Takeda's Firazyr.
Icatibant injection is indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
The product has a market value of roughly $137 million for the 12 months ended June 2023, per IQVIA.
[Read more: Aurobindo gets FDA nod for 3 generics]
The product will be unveiled in September.